Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:45:20.932Z.
Calculation as of: 2026-10-06T13:45:20.932Z.
Quote observation: 2026-10-06T13:43:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bd475241593d5c58f7737f650220a879a7f67ee05652ed27eb0102460b642cb0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Acrivon Therapeutics, Inc. Common Stock
Market Cap
$87.10M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$81.54M
PS Ratio
13.16
TTM Avg
5.23
3Y Avg
5.24
5Y Avg
18.61
Market Cap
$88.63M
PS Ratio
174.48
TTM Avg
221.52
3Y Avg
228.25
5Y Avg
248.51
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $87.10M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $85.52M | 12.04 | 16.63 | 16.63 | 16.63 |
| Humacyte, Inc. (HUMA)vs › | $84.52M | 39.85 | 49.38 | 546.61 | 880.05 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.83M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $87.54M | 0.68 | 0.94 | 0.55 | 0.51 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $81.54M | 13.16 | 5.23 | 5.24 | 18.61 |
| LENSAR Inc (LNSR)vs › | $81.80M | 1.36 | 2.06 | 1.84 | 1.67 |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | 174.48 | 221.52 | 228.25 | 248.51 |
| Conexeu Sciences Inc. (CNXU)vs › | $87.50M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $89.11M | 2.90 | 2.48 | 2.09 | 2.48 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-19 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
